Orthocell Ltd ( (AU:OCC) ) has issued an update.
Orthocell Limited announced the US FDA 510(k) clearance for its Remplir nerve repair product, marking a significant milestone for the company. This clearance is expected to enhance Orthocell’s market positioning in regenerative medicine, potentially benefiting stakeholders by expanding the product’s availability and application in the US market.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company based in Australia, specializing in products for the repair of bone and soft tissue injuries. Their portfolio includes collagen medical devices for dental and orthopedic applications, with products like Striate+™ and Remplir™ approved and distributed in various global markets. The company is also advancing tendon cell therapy development in the US.
YTD Price Performance: 5.51%
Average Trading Volume: 1,561,779
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$364.2M
See more data about OCC stock on TipRanks’ Stock Analysis page.